Top

World Journal of Urology

Published in:

01-09-2018 | Original Article

Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort

Authors: Viktor Grünwald, Marion Dietrich, Gregory R. Pond

Published in: World Journal of Urology | Issue 9/2018

Abstract

Purpose

Early tumor shrinkage (eTS) has prognostic value in metastatic renal cell carcinoma (mRCC). We aimed to validate the role of eTS in first line treatment from the COMPARZ study (NCT00720941).

Methods

1100 patients treated with sunitinib or pazopanib were analyzed for tumor response according to RECIST 1.0. eTS was defined as tumor shrinkage by ≥ 10%. A landmark analysis was performed on day (d) 42 and 90 and Cox proportional hazards regression was computed for the prognostic effect of eTS.

Results

In patients with eTS median OS was 34.1 [CI 95% 28.4; not reached (NR)] and 33.6 (CI 95% 30.1; NR) months (mo) at d 42 and 90, respectively, compared to 19.6 (CI 95% 14.0; 28.9) and 15.1 (CI 95% 12.4; 18.7) mo for patients without eTS. There was no interaction between type of treatment and eTS (d 42 p = 0.79; d 90 p = 0.37). eTS ≥ 10% remained an independent prognostic marker in multivariable analyses at both d 42 and 90.

Conclusions

Similar results were found for eTS at the 42 and 90 days landmarks. eTS ≥ 10% has prognostic relevance in mRCC and reflects a putative tool to guide future clinical treatment.

Available only for authorised users

Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722–731. https://doi.org/10.1056/NEJMoa1303989 CrossRefPubMed

Grünwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ et al (2015) Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol 67:952–958. https://doi.org/10.1016/j.eururo.2014.12.036 CrossRefPubMedPubMedCentral

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma 373:1803–1813. https://doi.org/10.1056/NEJMoa1510665 CrossRef

Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T et al (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16:1473–1482. https://doi.org/10.1016/S1470-2045(15)00290-9 CrossRefPubMed

Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F et al (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814–1823. https://doi.org/10.1056/NEJMoa1510016 CrossRefPubMedPubMedCentral

Grünwald V, Lin X, Kalanovic D, Simantov R (2016) Early tumour shrinkage: a tool for the detection of early clinical activity in metastatic renal cell carcinoma. Eur Urol 70:1006–1015. https://doi.org/10.1016/j.eururo.2016.05.010 CrossRefPubMed

Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S et al (2014) First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer 110:1917–1922. https://doi.org/10.1038/bjc.2014.25 CrossRefPubMedPubMedCentral

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V et al (2016) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:v58–v68. https://doi.org/10.1093/annonc/mdw328 CrossRefPubMed

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S et al (2016) European association of urology guidelines for clear cell renal cancers that are resistant to vascular endothelial growth factor receptor-targeted therapy. Eur Urol. https://doi.org/10.1016/j.eururo.2016.06.009 PubMedCentralCrossRefPubMed

10.

Doehn C, Grünwald V, Steiner T, Follmann M, Rexer H, Krege S (2016) The diagnosis, treatment, and follow-up of renal cell carcinoma. Dtsch Arztebl Int 113:590–596. https://doi.org/10.3238/arztebl.2016.0590 PubMedPubMedCentralCrossRef

11.

Calvo E, Schmidinger M, Heng DYC, Grünwald V, Escudier B (2016) Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat Rev 50:109–117. https://doi.org/10.1016/j.ctrv.2016.09.002 CrossRefPubMed

12.

Ornstein MC, Wood LS, Elson P, Allman KD, Beach J, Martin A et al (2017) A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma. J Clin Oncol 35:1764–1769. https://doi.org/10.1200/JCO.2016.71.1184 CrossRefPubMed

13.

Collinson FJ, Gregory WM, McCabe C, Howard H, Lowe C, Potrata D et al (2012) The STAR trial protocol: a randomised multi-stage phase II/III study of sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal cancer. BMC Cancer 12:598. https://doi.org/10.1186/1471-2407-12-598 CrossRefPubMedPubMedCentral

14.

Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG (2011) Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 60:1–7. https://doi.org/10.1016/j.eururo.2011.07.008 CrossRef

15.

Krajewski KM, Guo M, van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J et al (2011) Comparison of four early post therapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 59:856–862. https://doi.org/10.1016/j.eururo.2011.01.038 CrossRefPubMed

16.

Busch J, Seidel C, Goranova I, Erber B, Peters R, Friedersdorff F et al (2014) Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer 50:563–569. https://doi.org/10.1016/j.ejca.2013.10.017 CrossRefPubMed

17.

Motzer RJ, Sharma P, Escudier BJ, McDermott DF, George S, Srinivas S et al (2016) Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): results from the phase III CheckMate 025 study. J Clin Oncol 34:4552. https://doi.org/10.1200/JCO.2016.34.15_suppl.4552 CrossRef

18.

McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC et al (2015) Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 33:2013–2020. https://doi.org/10.1200/JCO.2014.58.1041 CrossRefPubMedPubMedCentral

19.

Krajewski KM, Nishino M, Ramaiya NH, Choueiri TK (2015) RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. AJR Am J Roentgenol 204:W282–W288. https://doi.org/10.2214/AJR.14.13236 CrossRefPubMedPubMedCentral

Title: Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort
Authors: Viktor Grünwald
Marion Dietrich
Gregory R. Pond
Publication date: 01-09-2018
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 9/2018
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2297-4

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2018

Diagnostic value of urinary survivin as a biomarker for bladder cancer: a systematic review and meta-analysis of published studies

Supra-pubic versus urethral catheter after robot-assisted radical prostatectomy: systematic review of current evidence

Thulium laser VapoResection of the prostate versus traditional transurethral resection of the prostate or transurethral plasmakinetic resection of prostate for benign prostatic obstruction: a systematic review and meta-analysis

Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer

Urologists’ attitudes to sexual complications of LUTS/BPH treatments

Epidemiology and screening for renal cancer